ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1549069
Cost-Effectiveness of Therapeutic Drug Monitoring of Perampanel for pediatrics with epilepsy: Real-World Data
Provisionally accepted
- Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Aims: Increased plasma concentration of perampanel (PER) is associated with reduction in seizure frequency. It is unclear how much better therapeutic drug monitoring (TDM) is than without TDM in pediatric using PER. This study aims to estimate the effectiveness and cost-effectiveness of TDM of PER in children with epilepsy.Methods: An observational study was conducted to compare clinical and economic outcomes between the TDM and non-TDM groups. We used a Markov model to evaluate the cost-effectiveness of TDM from a healthcare system perspective based on data from an observation cohort study that included four health states. High costeffectiveness thresholds were defined as < $12814. One-way, probabilistic sensitivity analyses and scenario analyses were conducted to explore uncertainty. Results: TDM of the PER improved the 1-year seizure-free rate from 16.7% to 48.1% and the >50% reduction in seizure frequency from 58.3% to 83.3% in children with epilepsy (P=0.035). The TDM of the PER is highly cost-effective, with an ICER of $732.90 per QALY gained (79.11% probability of being highly cost-effective). TDM was dominant, with an increased QALY of 0.86 and a decreased cost of $1586.07 in children with newly diagnosed epilepsy. The number of days of hospitalization in the no response state, which is related to the cost of hospitalization, is the largest influencing factor. Conclusions: TDM of PER could reduce the seizure frequency and is cost-effective for children with epilepsy. TDM of the PER in newly diagnosed epilepsy patients is strongly dominant because of its improvement in efficacy and reduction in cost.
Keywords: Therapeutic drug monitoring, Cost-Effectiveness, Pediatrics, efficacy, Epilepsy, Perampanel (PER)
Received: 23 Dec 2024; Accepted: 20 Jun 2025.
Copyright: © 2025 Hu, Miao, Chen, Mao, Wang, Feng, Chen, Yu and Dai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lingyan Yu, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Haibin Dai, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.